GlassScriptPhysician profile
Yanina Etlis
NPI 1730160920
$8,140.07
in general payments reported to CMS, 2019-2025
41 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $832 · 2021: $1,807 · 2022: $1,289 · 2023: $826 · 2024: $944 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,967.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,173.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $692.59 | 2019-2022 | |
| Amgen INC. | $600.61 | 2019-2025 | Evenity, Otezla, Prolia |
| Pfizer INC. | $415.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $411.10 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Lilly USA, LLC | $370.26 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $306.94 | 2019-2023 | Livalo |
| Merck Sharp & Dohme LLC | $255.63 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.47 | 2021-2024 | Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $227.44 | 2019-2025 | Camzyos, Eliquis |
| Sunovion Pharmaceuticals INC. | $219.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $136.44 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $107.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $86.52 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanina Etlis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.